Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)

Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including dopamine precursors, dopamine agonists, and MAO-B inhibitors. Individualized care, a high level of polypharmacy, and frequent medication adjustments as patients progress through lines of therapy are required for PD treatment. Several new brands have recently entered the competitive PD therapy market, including AbbVie’s Vyalev (foslevodopa / foscarbidopa subcutaneous pump), Amneal’s Crexont (levodopa / carbidopa ER), and Supernus’s Onapgo (apomorphine subcutaneous pump), and several emerging drugs are poised to launch in 2026 and beyond (e.g., Neuroderm’s ND0612, AbbVie’s tavapadon). A grasp of current market dynamics is crucial for both new and established players vying for a share of this increasingly competitive landscape.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PD patients?
• How have Crexont and Vyalev been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of PD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: AbbVie, Acadia, Amneal, Kyowa Kirin, Lundbeck, Merz, Supernus

Key drugs: Duopa, Gocovri, Inbrija, Neupro, Dhivy, Apokyn, Namerzic, Nourianz, Nuplazid, Ongentys, Rytary, Crexont, Vyalev, Onapgo, Xadago